Last reviewed · How we verify

NCT04371133

Anti-inflammatory Markers in Endometrioma

Completed Last updated 1 May 2020
What this trial tests

trial testing Adropin (ng/L) in Endometrioma in 48 participants. Completed in 15 March 2020.

Timeline
15 August 2018
Primary endpoint
15 February 2020
15 March 2020

Quick facts

Lead sponsorMuğla Sıtkı Koçman University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment48
Start date15 August 2018
Primary completion15 February 2020
Estimated completion15 March 2020
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Muğla Sıtkı Koçman University

Who can join

18 and older, female only, with Endometrioma or Inflammation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigators aimed to measure the serum levels of adropin, salusin-α, netrin-1, and nesfatin-1, anti-inflammatory effects of which have been demonstrated previously, in endometriosis patients and to find out any association of them with insulin resistance.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. The role of adropin, salusin-α, netrin-1, and nesfatin-1 in endometriosis and their association with insulin resistance
    Akbaba E, Sezgin B, Edgünlü T. · · 2021 · cited 9× · PMID 34580399 · DOI 10.4274/tjod.galenos.2021.12080

Verify or expand the search:

Other recruiting trials for Endometrioma

Currently open trials in the same condition.

Other Muğla Sıtkı Koçman University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04371133.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing